Thoratec Should Move Ahead on a Sale, Oracle Proposes in Filing
Thoratec Corp. (THOR), a maker of implantable heart pumps, should retain an investment bank to put the company up for sale, according to a shareholder proposal by investor Oracle Investment Management Inc.
The proposal for the next shareholder meeting was disclosed in a regulatory filing today. Oracle, based in Greenwich, Connecticut, controls 5.2 percent of Pleasanton, California- based Thoratec.
Larry Feinberg, Oracle’s founder, earlier this month urged Thoratec’s board to hire a bank to handle an auction of the company. The heart-pump maker may attract bids from Johnson & Johnson (JNJ), Medtronic Inc. (MDT) or Abbott Laboratories (ABT) if the company seeks a buyer, Feinberg said in an interview on Dec. 6.
“We believe that the market clout, capital resources, and relevant experience of a larger and more tenured medtech company is required to accelerate the penetration of this burgeoning market opportunity,” Oracle said in a supporting statement in the filing.
The market for Thoratec’s main product, the left- ventricular assist device, is $5 billion to $10 billion, Oracle said in its statement. A company device in development may generate as much as $1 billion, Oracle said.
Thoratec gained less than 1 percent to $30.71 at 10:16 a.m. New York time.
To contact the reporter on this story: Drew Armstrong in Washington at firstname.lastname@example.org;
To contact the editor responsible for this story: Reg Gale at email@example.com